CD8A and non-small cell lung carcinoma: In summary, the presence of CD8+FoxP3+PD-1+ cells in advanced NSCLC tissues and their close spatial proximity to tumor cells might be crucial for favorable survival outcomes in patients receiving immunotherapy.